Prenetics Global Limited (NASDAQ: PRE) announced a multi-year global partnership with actress Lily Collins, who joins as an IM8 global ambassador and shareholder. The deal marks the brand's expansion into entertainment.

Collins becomes the first IM8 ambassador from film and television, joining an equity-aligned roster that includes David Beckham and Giannis Antetokounmpo. She takes equity in Prenetics as part of the partnership, aligning her interests with the company's long-term performance.

Strategic Expansion

The partnership leverages Collins' social media reach of more than 33 million followers, including more than 28 million on Instagram. Her engagement rate of approximately 5.9% significantly exceeds the 1-2% benchmark for accounts of comparable scale. This provides IM8 with direct access to a multigenerational, female audience, a priority segment for the brand's next growth phase.

Collins discovered IM8 Daily Ultimate Essentials independently while filming in late 2025. She incorporated the product into her daily routine before any commercial agreement was discussed.

Financial Guidance and Momentum

Driven by IM8's growth, Prenetics raised its full-year 2026 revenue guidance to $220-$230 million. The company also initiated full-year 2027 revenue guidance of $400 million or more. Prenetics achieved positive consolidated Adjusted Free Cash Flow in July 2026 and expects to remain positive for the full third quarter of 2026 and beyond.

IM8 currently ships approximately 200,000 servings daily across 46 countries. Since launching in December 2024, the brand has delivered more than 57 million servings. International markets now contribute 54% of IM8's revenue.

What the Numbers Show

The company's revenue guidance implies significant top-line acceleration. Raising FY26 guidance to $220+ million while initiating FY27 guidance at $400+ million suggests management expects annualized revenue to nearly double within one fiscal year. This aggressive projection relies on sustained conversion from the current daily shipment rate of ~200,000 servings and successful international expansion, given that over half of revenue already originates outside the United States.

Product Pipeline

IM8 plans to launch IM8 Hydration in Q4 2026. A premium gummies line is scheduled for release in the first half of 2027. The flagship product, Daily Ultimate Essentials, contains 90 science-backed ingredients designed to replace 16 supplements in a single daily sachet.

Prenetics Global (NASDAQ: PRE) has provided full-year sales guidance for FY26, projecting revenue between $220.000 million and $230.000 million. The company’s outlook exceeds the consensus analyst estimate of $214.071 million, indicating a potential upside of approximately $5.9 million to $15.9 million over market expectations.

The guidance suggests that Prenetics Global anticipates robust performance across its business segments for the remainder of the fiscal year. By setting a floor of $220.000 million, the company is signaling confidence in its ability to outperform current market consensus by a margin of at least 2.8%.

What the Numbers Show

The divergence between the lower end of the guidance range and the analyst estimate highlights a notable shift in market sentiment versus management’s internal projections. While the analyst estimate sits at $214.071 million, the company’s conservative floor is $220.000 million. This gap implies that either recent operational developments have strengthened the company’s position beyond what analysts had priced in, or that previous estimates were based on more cautious assumptions regarding volume or pricing.

No other financial metrics, such as net profit, EBITDA, or segment-wise breakdowns, were disclosed in the filing. Investors will need to await further disclosures for a complete picture of profitability and margin trends alongside this top-line guidance.